A new study from the W. P. Carey School of Business at Arizona State University shows consumers believe prices for essential medicines are based on public need and not profit.
Rochelle Sampy speaks to Richard Bergström, Director General of the European Federation of Pharmaceutical Industries and Associations about the benefits Real World Evidence can bring to healthcare and how to alleviate very valid concerns about data privacy.
With the Indian government continuing to favor generics in their quest for affordable healthcare, pharma multinationals are now opting for aggressive preemptive strikes to protect profits via India's courts.
An academic perspective published in the New England Journal of Medicine makes an urgent call to the FDA to prevent unsafe medical devices from entering the marketplace.
China’s State Food and Drug Administration has announced proposals to reform the country’s drug registration process, including a special “fast-track” for generics which answer an unmet clinical need.
Pharmaceutical companies are moving away from developing ‘blockbuster’ drugs to creating new targeted biopharmaceutical treatments for ‘niche’ diseases, according to recent research.
The US Food and Drug Administration (FDA) has – for the first time – approved a patch that delivers the active drug transdermally to relieve migraine-related symptoms.
The Health Committee at the UK’s National Institute for Health and Clinical Excellence has urged the industry to rebuild trust with professionals and the public by making all clinical trial data available.
After a storm of commotion in light of Merck & Co’s drug Tredaptive, which was found (when added to statins) not to reduce major vascular events as it’s supposed to, the company has taken it upon themselves to update the public on the latest developments.